Abstract
Genetics intersects with environmental, cultural, and social factors in the development of addictive disorders. This study reports the feasibility of whole-exome sequencing of trios (subject and two family members) to discover potential genetic variants in the development of substance use disorders (SUD). Family trios were recruited from the National Addictions Management Service in Singapore during the 2016–2018 period. Recruited subjects had severe alcohol use disorder (AUD) or opioid use disorder (OUD), with nicotine dependence (ND) and a family history of addictive disorders. Demographic characteristics and severity of addiction were captured. Whole-exome sequencing (WES) and analysis were performed on salivary samples collected from the trios. WES revealed variants in several genes in each individual and disruptive protein mutations in most. Variants were identified in genes previously associated with SUDs, such as Pleckstrin homology domain-containing family M member 3 (PLEKHM3), coiled-coil serine-rich protein 1 (CCSER1), LIM and calponin homology domains-containing protein 1 (LIMCH1), dynein axonemal heavy chain 8 (DNAH8), and the taste receptor type 2 member 38 (TAS2R38) involved in the perception of bitterness. The feasibility study suggests that subjects with a severe addiction profile, polysubstance use, and family history of addiction may often harbor gene variants that may predispose them to SUDs. This study could serve as a model for future precision medicine-based personalized interventional strategies for behavioral addictions and SUDs and for the discovery of potentially pathogenic genetic variants.
Highlights
Our study explored the feasibility of conducting Whole-exome sequencing (WES) in the treatment-seeking population at the National Addictions Management Service (NAMS) Clinic of Singapore with the intent of identifying potential pathogenic variants, candidate genes, and the challenges in conducting such an exercise when constructing substance use disorders (SUD) treatments
The sample for this pilot study consisted of five trios—one subject and two family members per subject (n = 15)
Three subjects had a diagnosis of alcohol use disorder (AUD) and the other two of opioid use disorder (OUD) (Table 1)
Summary
Substance abuse is a leading cause of mortality and morbidity. 2019 shows that around 5.5% of the world’s population aged 15–64 years used drugs in the preceding 12 months [1]. When it comes to the most serious impact of substance abuse, over 47,000 deaths were reported in 2017 due to opioid overdose in the United. A 13% increase compared to the previous year [1]. Alcohol abuse accounted for ~3 million deaths in 2016, with over 2.7 billion estimated users aged 15 or above [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
